Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Swedbank AB

Swedbank AB increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 160.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,729 shares of the biopharmaceutical company’s stock after purchasing an additional 33,090 shares during the period. Swedbank AB’s holdings in Alnylam Pharmaceuticals were worth $14,777,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. O Shaughnessy Asset Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 9.6% during the first quarter. O Shaughnessy Asset Management LLC now owns 2,181 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 191 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 194.0% in the first quarter. Advisors Asset Management Inc. now owns 4,037 shares of the biopharmaceutical company’s stock valued at $603,000 after purchasing an additional 2,664 shares during the period. Kennedy Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter worth about $231,000. Tidal Investments LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 292.3% during the first quarter. Tidal Investments LLC now owns 10,281 shares of the biopharmaceutical company’s stock worth $1,536,000 after purchasing an additional 7,660 shares during the period. Finally, iA Global Asset Management Inc. boosted its position in Alnylam Pharmaceuticals by 28.2% in the first quarter. iA Global Asset Management Inc. now owns 7,765 shares of the biopharmaceutical company’s stock valued at $1,160,000 after buying an additional 1,710 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on ALNY shares. Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Bank of America increased their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Finally, Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $253.35 on Wednesday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market capitalization of $32.68 billion, a PE ratio of -96.70 and a beta of 0.39. The business’s 50 day moving average price is $272.74 and its 200-day moving average price is $239.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The firm’s quarterly revenue was down 33.3% on a year-over-year basis. During the same period last year, the firm earned $1.15 earnings per share. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.